destekleyen kurum bulunmamaktadır
İlgi ve alakanıza teşekürler
Background Thrombotic complications are the most considerable etiology causing morbidity and mortality in patients with philadelphia (Ph) negative myeloproliferative neoplasms (MPN). There are many studies evaluating the association of JAK2 mutation and risk of thrombosis in MPN with inconclusive results. We also investigated the relation between JAK2 mutation in all Ph negative MPN and thrombosis.
Material and Methods Thrombotic events and demographic features of 177 patients with Ph negative MPN were evaluated retrospectively.
Results JAK2 V617 F mutation was detected in 57% of patients with essential thrombocythemia (ET), %90.3 of pateints with polycythemia vera (PV), 100% of pateints with primary myelofibrosis (PMF). Thrombotic complications occured more frequently with JAK2 mutation in all MPN patients than without (p=0.014). In JAK 2 mutation positive groups, the median age, thrombosis risk scores and leucocyte values are higher, splenomegaly and arterial and/or venous thrombosis are detected more frequently (p<0.05). In subgroup analysis, there is a significant difference found in JAK 2 positive ET patients and negative group in case of thrombosis (p=0.023).
Conclusions JAK2 mutation and monitoring for thrombotic events should be performed in all MPN patients.
Thrombosis myeloproliferative neoplasms, essential thrombocytemia, polycythemia vera
Birincil Dil | İngilizce |
---|---|
Konular | İç Hastalıkları |
Bölüm | Original Articles |
Yazarlar | |
Yayımlanma Tarihi | 29 Temmuz 2022 |
Gönderilme Tarihi | 13 Ocak 2022 |
Kabul Tarihi | 21 Nisan 2022 |
Yayımlandığı Sayı | Yıl 2022 Cilt: 4 Sayı: 3 |